Indilix-T Tablet SR is a combination antihypertensive medication containing Telmisartan 40 mg and Indapamide 1.5 mg, formulated to provide sustained release for effective blood pressure control. Telmisartan, an angiotensin II receptor antagonist, selectively blocks the binding of angiotensin II to the AT1 receptor, thereby inhibiting vasoconstriction and aldosterone secretion, resulting in vasodilation and reduced peripheral resistance. Indapamide, a thiazide-like diuretic, promotes natriuresis and diuresis by inhibiting sodium reabsorption in the distal convoluted tubules, leading to decreased plasma volume and reduced blood pressure. The combination of these agents offers complementary mechanisms to achieve enhanced antihypertensive efficacy. Indilix-T Tablet SR is indicated for the treatment of essential hypertension, either as monotherapy or in patients inadequately controlled by monotherapy. The sustained-release formulation ensures a steady plasma concentration, improving patient compliance and minimizing fluctuations in blood pressure. Caution is advised in patients with renal or hepatic impairment, electrolyte imbalances, or hypersensitivity to sulfonamides. Regular monitoring of renal function, electrolytes, and blood pressure is recommended during therapy. Indilix-T Tablet SR should be used under medical supervision, with dosage adjustments based on clinical response and tolerability.